X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (187) 187
Publication (32) 32
Book Review (29) 29
Book Chapter (14) 14
Conference Proceeding (13) 13
Book / eBook (2) 2
Reference (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (131) 131
humans (127) 127
oncology (105) 105
female (67) 67
male (57) 57
middle aged (54) 54
adult (51) 51
aged (51) 51
cancer (50) 50
antineoplastic agents - therapeutic use (35) 35
treatment outcome (33) 33
clinical trials (31) 31
neoplasms - drug therapy (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
chemotherapy (26) 26
care and treatment (25) 25
cell lung-cancer (24) 24
research (23) 23
article (21) 21
clinical trials as topic (21) 21
quinazolines - therapeutic use (21) 21
tyrosine kinase inhibitor (21) 21
hematology, oncology and palliative medicine (20) 20
quinazolines - administration & dosage (20) 20
maximum tolerated dose (19) 19
receptor, epidermal growth factor - antagonists & inhibitors (19) 19
aged, 80 and over (18) 18
erlotinib hydrochloride (18) 18
expression (17) 17
sirolimus - analogs & derivatives (17) 17
erlotinib (16) 16
growth-factor receptor (16) 16
neoplasm recurrence, local - drug therapy (16) 16
pharmacology & pharmacy (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
disease progression (15) 15
gefitinib (14) 14
health aspects (14) 14
quinazolines - adverse effects (14) 14
solid tumors (14) 14
antineoplastic agents - adverse effects (13) 13
antineoplastic combined chemotherapy protocols - pharmacokinetics (13) 13
disease-free survival (13) 13
follow-up studies (13) 13
oncology, experimental (13) 13
sirolimus - therapeutic use (13) 13
therapy (13) 13
brain neoplasms - drug therapy (12) 12
child (12) 12
medicine & public health (12) 12
trial (12) 12
carcinoma (11) 11
dose-response relationship, drug (11) 11
mammalian target (11) 11
medical research (11) 11
protein kinase inhibitors - therapeutic use (11) 11
quality of life (11) 11
rheumatology (11) 11
survival analysis (11) 11
temsirolimus (11) 11
antineoplastic agents (10) 10
clinical-trials (10) 10
drug administration schedule (10) 10
drug therapy (10) 10
neoplasm metastasis (10) 10
pharmacology/toxicology (10) 10
tumors (10) 10
antimitotic agents (9) 9
antineoplastic agents - administration & dosage (9) 9
breast neoplasms - drug therapy (9) 9
infusions, intravenous (9) 9
lung neoplasms - drug therapy (9) 9
metastasis (9) 9
neoplasms - pathology (9) 9
prognosis (9) 9
rapamycin (9) 9
abridged index medicus (8) 8
adolescent (8) 8
arthritis (8) 8
breast-cancer (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
carcinoma, squamous cell - drug therapy (8) 8
child, preschool (8) 8
children (8) 8
epidermal growth factor (8) 8
head and neck neoplasms - drug therapy (8) 8
mtor (8) 8
mutations (8) 8
neoplasm staging (8) 8
neoplasms - genetics (8) 8
neoplasms - therapy (8) 8
phase-ii (8) 8
sirolimus - adverse effects (8) 8
sorafenib (8) 8
toxicity (8) 8
animals (7) 7
antibodies, monoclonal, humanized (7) 7
antineoplastic agents - pharmacokinetics (7) 7
antineoplastic agents - pharmacology (7) 7
bevacizumab (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 06/2015, Volume 121, Issue 11, pp. 1728 - 1730
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 3, pp. 247 - 257
Summary Background Epidermal growth factor receptor (EGFR) is a validated target in squamous-cell carcinoma of the head and neck, but in patients with... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER CELLS | CETUXIMAB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | II TRIAL | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | EGFR | ENDOTHELIAL GROWTH-FACTOR | Erlotinib Hydrochloride | Multivariate Analysis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Vascular Endothelial Growth Factor Receptor-2 - analysis | Head and Neck Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - analysis | Regression Analysis | Carcinoma, Squamous Cell - drug therapy | Transforming Growth Factor alpha - analysis | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Head and Neck Neoplasms - mortality | Care and treatment | Carcinoma | Biological products | Oncology, Experimental | Metastasis | Research | Endothelium | Epidermal growth factor | Erlotinib | Universities and colleges | Health aspects | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. SY03-01 - SY03-01
Journal Article
Clinical Biochemistry, ISSN 0009-9120, 04/2012, Volume 45, Issue 6, pp. 379 - 381
Journal Article
2012, ISBN 364216482X, Volume 7, 3
Reference
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4740 - 4746
Purpose Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a... 
MAMMALIAN TARGET | TRIAL | ACTIVATION | ONCOLOGY | RAPAMYCIN INHIBITOR EVEROLIMUS | CYCLIN D1 | C-MYC | FOLLICULAR LYMPHOMA | CANCER | EXPRESSION | MTOR | Lymphoma, Follicular - drug therapy | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Intracellular Signaling Peptides and Proteins - metabolism | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Protein-Serine-Threonine Kinases - metabolism | Sirolimus - adverse effects | Bone Marrow - drug effects | Lymphoma, Non-Hodgkin - drug therapy | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Chicago | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Remission Induction | Mucositis - chemically induced | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Lymphoma, Non-Hodgkin - metabolism | Protein-Serine-Threonine Kinases - drug effects | Aged | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Index Medicus | Original Reports | Hema13 | Hema15
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2010, Volume 102, Issue 10, pp. 670 - 671
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 01/2015, Volume 13, Issue 1, pp. 23 - 25
Journal Article
by Ombrello, Michael J and Remmers, Elaine F and Tachmazidou, Ioanna and Grom, Alexei and Foell, Dirk and Haas, Johannes-Peter and Martini, Alberto and Gattorno, Marco and Özen, Seza and Prahalad, Sampath and Zeft, Anew S and Bohnsack, John F and Mellins, Elizabeth D and Ilowite, Norman T and Russo, Ricardo and Len, Claudio and Hilario, Maria Odete E and Oliveira, Sheila and Yeung, Rae S M and Rosenberg, Alan and Wedderburn, Lucy R and Anton, Jordi and Schwarz, Tobias and Hinks, Anne and Bilginer, Yelda and Park, Jane and Cobb, Joanna and Satorius, Colleen L and Han, Buhm and Baskin, Elizabeth and Signa, Sara and Duerr, Richard H and Achkar, J P and Kamboh, M Ilyas and Kaufman, Kenneth M and Kottyan, Leah C and Pinto, Dalila and Scherer, Stephen W and Alarcón-Riquelme, Marta E and Docampo, Elisa and Estivill, Xavier and Gül, Ahmet and de Bakker, Paul I W and Raychaudhuri, Soumya and Langefeld, Carl D and Thompson, Susan and Zeggini, Eleftheria and Thomson, Wendy and Kastner, Daniel L and Woo, Patricia and Int Childhood Arthritis Genetics and BSPAR Study Grp and BBOP Grp and Randomized Placebo Phase Study and CHARMS Grp and Childhood Arthritis Prospective Study (CAPS) Group and International Childhood Arthritis Genetics (INCHARGE) Consortium and British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group and Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators and Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group and Biologically Based Outcome Predictors in JIA (BBOP) Group
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2015, Volume 112, Issue 52, pp. 15970 - 15975
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2011, Volume 67, Issue 6, pp. 1225 - 1237
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 23, pp. 5294 - 5304
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2015, Volume 74, Issue 10, pp. 1854 - 1860
Journal Article